Estrogen receptor positive locally advanced breast cancer in postmenopausal women, Estrogen receptor positive metastatic breast cancer in postmenopausal women
Adult: As monotherapy for those who are not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy: 500 mg (250 mg into each buttock) on days 1, 15, and 29, then once monthly thereafter.
Intramuscular
Hormone receptor positive, HER2-negative locally advanced carcinoma of breast, Hormone receptor positive, HER2-negative metastatic carcinoma of breast
Adult: In combination with palbociclib or abemaciclib, in women with disease progression following endocrine therapy: 500 mg (250 mg into each buttock) on days 1, 15, and 29, then once monthly thereafter. Continue until disease progression or unacceptable toxicity.
Intramuscular
Hormone receptor positive, HER2-negative locally advanced breast cancer in postmenopausal women, Hormone receptor positive, HER2-negative metastatic breast cancer in postmenopausal women
Adult: In combination with ribociclib, as initial endocrine-based therapy or following disease progression on endocrine therapy: 500 mg (250 mg into each buttock) on days 1, 15, and 29, then once monthly thereafter. Continue until disease progression or unacceptable toxicity.